Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 10/20 | 0.49 |
| ▸ | RCOR1 | Q9UKL0 | 10/20 | 0.49 |
| ▸ | EHMT2 | Q96KQ7 | 7/20 | 0.49 |
| ▸ | KMT5A | Q9NQR1 | 3/20 | 0.47 |
| ▸ | SYK | P43405 | 3/20 | 0.45 |
| ▸ | ACP1 | P24666 | 3/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23015322 | 1.00 | KDM1A (0.49) | KDM1ARCOR1EHMT2KMT5ASYK | |
| SCHEMBL29636709 | 0.89 | SYK (0.46) | KMT5ASYKACP1 | |
| SCHEMBL23029732 | 0.89 | SYK (0.44) | EHMT2KMT5ASYKACP1 | |
| SCHEMBL23029767 | 0.89 | SYK (0.46) | KMT5ASYKACP1 | |
| SCHEMBL23029700 | 0.85 | SLC2A1 (0.60) | ACP1SLC2A1 | |
| SCHEMBL29636791 | 0.85 | ACP1 (0.52) | SYKACP1SLC2A1 | |
| SCHEMBL23015376 | 0.85 | ACP1 (0.52) | SYKACP1SLC2A1 | |
| Hydrochloric Acid SCHEMBL29636760 | 0.84 | SLC2A1 (0.59) | ACP1SLC2A1 | |
| SCHEMBL23015284 | 0.83 | EHMT2 (0.59) | KDM1ARCOR1EHMT2KMT5ASYK | |
| SCHEMBL23029743 | 0.83 | KDM1A (0.54) | KDM1ARCOR1EHMT2SYKACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4017492-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | Biohaven Therapeutics Ltd. (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-114667145-A | Molecules that bind to TDP-43 for the treatment of amyotrophic lateral sclerosis and related disorders | 拜尔哈文制药股份有限公司 | 2022-06-24 | — | — | CN | disclosed |